Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93)
Phase 4
15 Years
65 Years
15 Years
65 Years
Not Enrolling
Both
Adult Acute Lymphocytic Leukemia
Both
Adult Acute Lymphocytic Leukemia
Trial Information
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93)
Inclusion Criteria:
- Acute Lymphocytic Leukemia
- Age 15 - 65 years
Exclusion Criteria:
- Serious secondary diseases which may compromise intensified chemotherapeutical
treatment
- Serious psychiatric diseases, which may compromise compliance with therapy
- HIV-1 or HIV-2 Infection
- Pretreatment > 2 weeks or chemotherapy other than Vincristine and Steroids
- Patients without central diagnosis who cannot be allocated to a risk group
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
remission rate, disease free survival, overall survival
Principal Investigator
Dieter Hoelzer, MD, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
University of Frankfurt, Medical Department II
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
GMALL09
NCT ID:
NCT00199069
Start Date:
April 1993
Completion Date:
Related Keywords:
- Adult Acute Lymphocytic Leukemia
- ALL
- Treatment
- De Novo
- Adult
- Leukemia
- Leukemia, Lymphoid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Name | Location |
|---|
